Trial reportAntimicrobial agents and chemotherapy2010
Effect of ceftaroline on normal human intestinal microflora.
Trial report in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota.Antimicrobial agents and chemotherapy · 2015Trial
- Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci andPathogens & immunity · 2024Article
- Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Penicillin-Binding Proteins and Alternative Dual-Beta-Lactam Combinations for Serious Enterococcus faecalis Infections with Elevated Penicillin MICs.Antimicrobial agents and chemotherapy · 2023Article
- The effect of novel antimicrobial agents on the normal functioning of human intestinal microbiota: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in anAntimicrobial agents and chemotherapy · 2022Article
- Silver Nanoparticles and Its Mechanistic Insight for Chronic Wound Healing: Review on Recent Progress.Molecules (Basel, Switzerland) · 2022Review
- Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.The Journal of antimicrobial chemotherapy · 2019Article
- A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Review
- Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics.Infection and drug resistance · 2018Review
- Role of cephalosporins in the era of Clostridium difficile infection.The Journal of antimicrobial chemotherapy · 2017Review
- Gut Microbiota-brain Axis.Chinese medical journal · 2016Review
- Veterinary Medicine Needs New Green Antimicrobial Drugs.Frontiers in microbiology · 2016Review
- Ceftaroline fosamil: a brief clinical review.Infectious diseases and therapy · 2013Article
- Review
- Review
- Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.Infection and drug resistance · 2012Article
- Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Clinical medicine reviews in therapeutics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftaroline is a new broad-spectrum cephalosporin being developed for the treatment of serious bacterial infections, including those caused by aerobic Gram-positive and Gram-negative bacteria. The purpose of the present study was to investigate the effect of administration of ceftaroline on the intestinal flora of healthy subjects. Twelve healthy subjects (6 males and 6 females), 20 to 41 years of age, received ceftaroline (600 mg) by intravenous infusion every 12 h (q12h) for 7 days. Plasma and feces were collected for determination of ceftaroline concentration and analysis of fecal flora. Fecal specimens were cultured on nonselective and selective media. Different colony types were counted, isolated in pure culture, and identified to the genus level. All new strains of colonizing bacteria were tested for susceptibility to ceftaroline. The concentrations of ceftaroline in plasma were as follows: on day 2, 17.5 to 34.8 mg/liter; on day 5, 19.7 to 33.2 mg/liter; and on day 7, 18.0 to 29.8 mg/liter. No ceftaroline concentrations were found on day -1, 9, 14, or 21. No measurable concentrations in feces were found on day -1, 2, 5, 7, 9, 14, or 21. There was a minor impact on the numbers of Escherichia coli strains, while the numbers of enterococci and Candida albicans strains were not affected. There were moderate decreases in the numbers of bifidobacteria and lactobacilli during the first 7 days, while the numbers of clostridia increased during the same period. No impact on the numbers of Bacteroides bacteria was noticed. No new colonizing aerobic or anaerobic bacteria resistant to ceftaroline (MIC >or= 4 mg/liter) were found. Ceftaroline had no significant ecological impact on the human intestinal microflora.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.